Third, drugs that alter lipid and FA homeostasis in addition to SCD inhibitors may become promising targets.14–16 Fourth, the common assumption that proteinopathy means amyloid aggregation may have to be modified in the case of αS in PD and DLB. This evidence concerns the gene SCD and Parkinson disease.